| ISIN | LU0426487442 |
|---|---|
| Valor Number | 10173746 |
| Bloomberg Global ID | BBG000LZWTW4 |
| Fund Name | PPF ("PMG Partners Funds") - Helix Biotechnology Fund I |
| Fund Provider |
PMG Investment Solutions AG
Zug, Schweiz Phone: +41 44 215 28 38 E-Mail: pmg@pmg.swiss Web: https://www.pmg.swiss |
| Fund Provider | PMG Investment Solutions AG |
| Representative in Switzerland |
PMG Investment Solutions AG Zug Phone: +41 44 215 28 38 |
| Distributor(s) |
PMG Investment Solutions AG Zug Phone: +41 44 215 28 38 |
| Asset Class | Equities |
| EFC Category | |
| Distribution Policy | Accumulation |
| Home Country | Luxembourg |
| Issuing Condition | The fund management company and/or distributor charges an issuing commission (different commissions can be charged for the same fund depending on the sales channel) |
| Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
| Investment Strategy *** | The objective of the investment policy of the Subfund is to achieve the highest possible long-term capital growth in US dollars by taking advantage of the opportunities offered by biotech and pharmaceutical shares on the global stock markets. This involves investing in listed shares of companies that specialise in the identification, development and production of innovative chemical products for the healthcare sector. To achieve the investment objectives, the subfund will primarily invest in equities and, in part, in futures and exchange-traded options. The country-specific focus of the Fund is on the United States, Europe and the Asia region. This focus also includes investments in emerging markets in Europe and Asia. Investments are made in securities irrespective of their market capitalisation (small cap, mid cap, large cap). Up to 10% of the assets of the subfund may also be invested in China Connect Securities via the Stock Connect Programme. |
| Peculiarities |
| Current Price * | 115.64 USD | 08.01.2026 |
|---|---|---|
| Previous Price * | 117.36 USD | 07.01.2026 |
| 52 Week High * | 117.36 USD | 07.01.2026 |
| 52 Week Low * | 73.04 USD | 08.04.2025 |
| NAV * | 115.64 USD | 08.01.2026 |
| Issue Price * | ||
| Redemption Price * | ||
| Closing Price * | ||
| Indicative Minimum Price | ||
| Fund Assets *** | 31,539,800 | |
| Unit/Share Assets *** | 11,273,911 | |
| Trading Information SIX | ||
| YTD Performance | +2.16% |
31.12.2025 - 08.01.2026
31.12.2025 08.01.2026 |
|---|---|---|
| YTD Performance (in CHF) | +2.90% |
31.12.2025 - 08.01.2026
31.12.2025 08.01.2026 |
| 1 month | +1.57% |
08.12.2025 - 08.01.2026
08.12.2025 08.01.2026 |
| 3 months | +16.30% |
08.10.2025 - 08.01.2026
08.10.2025 08.01.2026 |
| 6 months | +44.80% |
08.07.2025 - 08.01.2026
08.07.2025 08.01.2026 |
| 1 year | +37.06% |
08.01.2025 - 08.01.2026
08.01.2025 08.01.2026 |
| 2 years | +28.45% |
08.01.2024 - 08.01.2026
08.01.2024 08.01.2026 |
| 3 years | +25.93% |
09.01.2023 - 08.01.2026
09.01.2023 08.01.2026 |
| 5 years | -18.28% |
08.01.2021 - 08.01.2026
08.01.2021 08.01.2026 |
| Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI Date | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc | 6.72% | |
|---|---|---|
| Vertex Pharmaceuticals Inc | 4.67% | |
| Gilead Sciences Inc | 4.58% | |
| Amgen Inc | 4.48% | |
| Incyte Corp | 4.01% | |
| Neurocrine Biosciences Inc | 3.23% | |
| Septerna Inc | 3.15% | |
| Intellia Therapeutics Inc | 3.02% | |
| Esperion Therapeutics Inc | 3.01% | |
| Biogen Inc | 2.91% | |
| Last data update | 30.09.2025 | |
| TER | 2.29% |
|---|---|
| TER date | 31.12.2024 |
| Performance Fee *** | 20.00% |
| PTR | |
| Max. Management Fee *** | 1.20% |
| Ongoing Charges *** | 1.75% |
|
SRRI ***
|
|
| SRRI date *** | 31.12.2025 |